Drug intelligence / Profile preview

EOC237

Development stage: Phase 1
Lead developer: Shanghai Yiteng Jingang Bio-pharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

EOC237 is an investigational, orally bioavailable small molecule inhibitor that targets the fibroblast growth factor receptors 1, 2, and 3 (FGFR1/2/3). Developed by EOC Pharma (Shanghai Yiteng Jingang Bio-pharmaceutical Technology), EOC237 is designed to treat advanced solid tumors characterized by FGFR alterations, such as gene amplifications, mutations, or fusions. By selectively inhibiting FGFR signaling, the drug aims to disrupt tumor cell proliferation and survival pathways. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in patients with advanced malignancies that have progressed on standard therapies.

Targets

CDK7

Beyond the preview

Go deeper on EOC237.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EOC237.

Explore the full profile